Semaglutide vs. Tirzepatide: Which Weight Loss Medication Is Better?

The two most effective classes of weight loss medication available today are semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro). Both are once-weekly injectables. Both work on GLP-1 receptors. But they differ in mechanism, efficacy, and side effect profile in important ways.

Mechanism of action

Semaglutide is a GLP-1 receptor agonist — it activates one receptor pathway (GLP-1) to reduce appetite, slow gastric emptying, and improve insulin sensitivity.

Tirzepatide is a dual GLP-1/GIP receptor agonist — it activates two receptor pathways simultaneously. The addition of GIP (glucose-dependent insulinotropic polypeptide) activation appears to enhance fat metabolism, improve muscle preservation, and reduce gastrointestinal side effects compared to GLP-1-only agents.

Head-to-head efficacy

Why does the dual mechanism matter?

GIP receptor activation does several things that GLP-1 alone doesn't:

• Enhanced fat oxidation: GIP signaling in adipose tissue increases the rate at which your body burns stored fat for energy
• Muscle preservation: The GIP pathway helps maintain lean muscle mass during weight loss — critical for long-term metabolic health and avoiding the "skinny fat" outcome
• Better GI tolerability: GIP appears to buffer some of the gastrointestinal effects of GLP-1 activation, explaining the dramatically lower nausea rates
• Improved insulin sensitivity: Dual activation provides more robust improvements in blood sugar regulation

Which should you choose?

For most patients, the clinical data favors dual-agonist formulations: better weight loss, fewer side effects, and better muscle preservation. However, the right medication depends on your individual medical history, current medications, and treatment goals. This is why a physician evaluation — not a Google search — should drive your decision.

At Linux Health, our physicians evaluate each patient individually and prescribe the treatment that's clinically most appropriate for your profile. Most patients receive a dual GLP-1/GIP agonist, but your physician will discuss the reasoning behind your specific prescription.

Medically reviewed by Dr. Rachel Morrison, MD, ABOM. Updated July 2026.